PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 17.5% in January

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 357,100 shares, a decrease of 17.5% from the December 31st total of 432,900 shares. Currently, 3.7% of the shares of the company are short sold. Based on an average daily volume of 153,700 shares, the days-to-cover ratio is currently 2.3 days.

PAVmed Stock Performance

Shares of PAVM traded down $0.00 during mid-day trading on Monday, hitting $0.66. 206,183 shares of the stock were exchanged, compared to its average volume of 204,190. The company has a market cap of $7.31 million, a PE ratio of -0.15 and a beta of 0.73. PAVmed has a 52-week low of $0.57 and a 52-week high of $3.50. The firm has a 50-day moving average of $0.73 and a two-hundred day moving average of $0.95.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their price target on PAVmed from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.